D Shorter1, J A Lindsay, T R Kosten. 1. The Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, and Michael E. DeBakey V.A. Medical Center, Houston, TX, United States. shorter@bcm.edu
Abstract
BACKGROUND: Medications decreasing central noradrenergic activity have been associated with attenuation of cocaine effects. AIMS: This pilot study examined the efficacy of doxazosin versus placebo for reducing cocaine use in treatment-seeking cocaine dependent persons. METHODS: We screened 108 cocaine dependent subjects and assigned 35 participants to receive eitherdoxazosin (8mg/day) or placebo for 13 weeks. Participants were titrated on the study medication according to two different schedules. During the initial phase of the study, patients were titrated onto the study medication over an 8-week period (DOX-slow). After reviewing data from our human laboratory study, a second phase was initiated, wherein titration was accelerated to a 4-week period (DOX-fast). All participants received weekly cognitive behavioral therapy. Urine toxicology was performed thrice weekly. RESULTS: Baseline subject characteristics were comparable. Thirty subjects entered the study: 8 subjects in DOX-slow, 9 subjects in DOX-fast, and 13 subjects inplacebo. Total number of cocaine-negative urines was significantly increased in the DOX-fast group; and percentage of total cocaine-negative urines by group were 10% for DOX-slow group, 35% for DOX-fast group, and 14% for placebo (χ(2)=36.3, df=2, p<0.0001). The percentage of participants achieving two or more consecutive weeks of abstinence by group was 0% for DOX-slow group, 44% for DOX-fast group, and 7% for placebo (χ(2)=7.35, df=2, p<0.023). CONCLUSIONS: This pilot study suggests the potential efficacy of doxazosin when rapidly titrated in reducing cocaine use. Published by Elsevier Ireland Ltd.
RCT Entities:
BACKGROUND: Medications decreasing central noradrenergic activity have been associated with attenuation of cocaine effects. AIMS: This pilot study examined the efficacy of doxazosin versus placebo for reducing cocaine use in treatment-seeking cocaine dependent persons. METHODS: We screened 108 cocaine dependent subjects and assigned 35 participants to receive either doxazosin (8mg/day) or placebo for 13 weeks. Participants were titrated on the study medication according to two different schedules. During the initial phase of the study, patients were titrated onto the study medication over an 8-week period (DOX-slow). After reviewing data from our human laboratory study, a second phase was initiated, wherein titration was accelerated to a 4-week period (DOX-fast). All participants received weekly cognitive behavioral therapy. Urine toxicology was performed thrice weekly. RESULTS: Baseline subject characteristics were comparable. Thirty subjects entered the study: 8 subjects in DOX-slow, 9 subjects in DOX-fast, and 13 subjects in placebo. Total number of cocaine-negative urines was significantly increased in the DOX-fast group; and percentage of total cocaine-negative urines by group were 10% for DOX-slow group, 35% for DOX-fast group, and 14% for placebo (χ(2)=36.3, df=2, p<0.0001). The percentage of participants achieving two or more consecutive weeks of abstinence by group was 0% for DOX-slow group, 44% for DOX-fast group, and 7% for placebo (χ(2)=7.35, df=2, p<0.023). CONCLUSIONS: This pilot study suggests the potential efficacy of doxazosin when rapidly titrated in reducing cocaine use. Published by Elsevier Ireland Ltd.
Authors: Jason P Schroeder; Debra A Cooper; Jesse R Schank; Megan A Lyle; Meriem Gaval-Cruz; Yvonne E Ogbonmwan; Nikita Pozdeyev; Kimberly G Freeman; P Michael Iuvone; Gaylen L Edwards; Philip V Holmes; David Weinshenker Journal: Neuropsychopharmacology Date: 2010-08-25 Impact factor: 7.853
Authors: I L Petrakis; K M Carroll; C Nich; L T Gordon; E F McCance-Katz; T Frankforter; B J Rounsaville Journal: Addiction Date: 2000-02 Impact factor: 6.526
Authors: Alison Oliveto; James Poling; Michael J Mancino; Zachary Feldman; Joseph F Cubells; Rhonda Pruzinsky; Kishorchandra Gonsai; Christopher Cargile; Mehmet Sofuoglu; Mohit P Chopra; Gerardo Gonzalez-Haddad; Kathleen M Carroll; Thomas R Kosten Journal: Drug Alcohol Depend Date: 2010-09-15 Impact factor: 4.492
Authors: Thomas F Newton; Richard De La Garza; Gregory Brown; Thomas R Kosten; James J Mahoney; Colin N Haile Journal: PLoS One Date: 2012-02-03 Impact factor: 3.240
Authors: George A Kenna; Carolina L Haass-Koffler; William H Zywiak; Steven M Edwards; Michael B Brickley; Robert M Swift; Lorenzo Leggio Journal: Addict Biol Date: 2015-06-02 Impact factor: 4.280
Authors: Terril L Verplaetse; Andrea H Weinberger; Lindsay M Oberleitner; Kathryn Mz Smith; Brian P Pittman; Julia M Shi; Jeanette M Tetrault; Meaghan E Lavery; Marina R Picciotto; Sherry A McKee Journal: J Psychopharmacol Date: 2017-04-25 Impact factor: 4.153
Authors: Xuefeng Zhang; David A Nielsen; Coreen B Domingo; Daryl I Shorter; Ellen M Nielsen; Thomas R Kosten Journal: Addict Biol Date: 2018-03-02 Impact factor: 4.280
Authors: Tracy L Simpson; Andrew J Saxon; Cynthia Stappenbeck; Carol A Malte; Robert Lyons; Dana Tell; Steven P Millard; Murray Raskind Journal: Am J Psychiatry Date: 2018-08-29 Impact factor: 18.112
Authors: Walter Roberts; Terril L Verplaetse; Kelly E Moore; Lindsay M Oberleitner; Sherry A McKee Journal: Hum Psychopharmacol Date: 2018-05 Impact factor: 1.672
Authors: Sudie E Back; Julianne C Flanagan; Jennifer L Jones; Isabel Augur; Alan L Peterson; Stacey Young-McCaughan; David W Shirley; Aisling Henschel; Jane E Joseph; Brett T Litz; Allison K Hancock; John D Roache; Jim Mintz; Jennifer S Wachen; Terence M Keane; Kathleen T Brady Journal: Contemp Clin Trials Date: 2018-08-24 Impact factor: 2.226